Background/Objectives: Nurse-like cells (NLCs) derived from monocytes in the tumor microenvironment support the growth of chronic lymphocytic leukemia (CLL) cells. Here, we investigated the effects of a CX3CR1 (fractalkine receptor) antagonist (KAND567) on autologous monocytes and their pro-survival effects on CLL cells in vitro. Methods: Plasma concentration of CX3CL1 was determined by ELISA and CX3CR1 expression by flow cytometry. CD19+ cells and autologous monocytes from patients with CLL and healthy donors were treated with KAND567 either in co-culture or alone. The apoptosis of CD19+ cells and monocytes was determined by Annexin V/PI staining and live-cell imaging. Results: Plasma concentration of CX3CL1 (fractalkine) was significantly higher in patients with CLL (n = 88) than in healthy donors (n = 32) (p < 0.0001), with higher levels in patients with active compared to non-active disease (p < 0.01). CX3CR1 was found on monocytes but not B cells in patients and controls. Levels of intermediate and non-classical CX3CR1+ monocytes were higher in patients with CLL than in controls (p < 0.001), particularly in those with active disease (p < 0.0001). Co-culture experiments revealed that autologous monocytes promoted the survival of both malignant and normal B cells and that KAND567 selectively inhibited the growth of CLL cells in a dose-dependent manner but only in the presence of autologous monocytes (p < 0.05). Additionally, KAND567 inhibited the transition of monocytes to NLCs in CLL (p < 0.05). Conclusions: Our data suggest that the CX3CR1/CX3CL1 axis is activated in CLL and may contribute to the NLC-driven growth-promoting effects of CLL cells. KAND567, which is in clinical trials in other disorders, should also be explored in CLL.
1 August 2020 in Journal of Biobased Materials and Bioenergy
Plumbago zeylanica L. (PZ) is a folk medicine for liver damage. To further explore its mechanism of action, a rat model of liver injury induced by carbon tetrachloride (CCl4) was used to evaluate the protective effect of PZ water extract (PZE). The results showed that PZE normalized the CCl4-induced serum levels of liver function index, hyaluronic acid (HA), superoxide dismutase (SOD), malondialdehyde (MDA), and decreased the hydroxyproline (Hyp) level in liver tissue. PZE also reduced the histological injuries induced by CCl4. In conclusion, these data demonstrated the hepatoprotective activities of PZE that may be related to its antioxidant properties.
Resistance to Bruton tyrosine kinase (TK) and BCL2 inhibitors, such as ibrutinib (Ibru) and venetoclax (Ven), remains a major therapeutic challenge in mantle cell lymphoma (MCL), which limits treatment options. Receptor TK-like orphan receptor 1 (ROR1), aberrantly expressed in MCL and other malignancies but largely absent in normal adult tissues, has been implicated in tumor cell proliferation, survival, and migration. This study aimed to elucidate the mechanisms underlying Ibru and Ven resistance in MCL and to investigate the therapeutic potential of targeting ROR1 using the small-molecule inhibitor KAN571C in Ibru- and/or Ven-resistant MCL cell lines. Ibru-, Ven-, and Ibru + Ven (Double)-resistant models were generated from the JEKO-1, Granta-519, and Z138 MCL cell lines. The cytotoxic effects of Ibru, Ven, and KAN571C were assessed in both naive and drug-resistant models using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays. Western blotting was used to analyze downstream signaling alterations after exposure to KAN571C. KAN571C induced potent cytotoxicity in both naive and drug-resistant models, preferentially in Ven- and Ibru/Ven-resistant cells. Mechanistically, KAN571C dephosphorylated ROR1 at TK and proline-rich domains, suppressed downstream phosphatidylinositol 3-kinase/AKT and β-catenin signaling, and activated caspase-dependent apoptosis. Notably, long-term exposure (2 weeks) failed to establish KAN571C-resistant cell lines. Our findings identify ROR1 as a convergent mediator of resistance in MCL and highlight KAN571C as a potential therapeutic strategy to overcome treatment refractoriness.